Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR
WardsAuto -

- Excellent safety and low target lesion revascularization (TLR) rates persist -

DURHAM, N.C., May 23, 2018 /PRNewswire/ -- A 24-month update on the DESSOLVE III trial of the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System

read more

Loading...

Related Articles